Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc compare based on key financial metrics to determine which better meets your investment needs.

About Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Latest Pharmaceuticals and Bayer Aktiengesellschaft, Bayer Aktiengesellschaft Stock News

As of July 30, 2026, Bayer Aktiengesellschaft had a $54.5 billion market capitalization, compared to the Pharmaceuticals median of $569.9 million. Bayer Aktiengesellschaft’s stock is up 28.3% in 2026, up 5.8% in the previous five trading days and up 70.37% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $52.2 billion with a -4.8% net profit margin. As of July 30, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.158 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

As of July 30, 2026, Bayer Aktiengesellschaft had a $54.5 billion market cap, putting it in the 94th percentile of all stocks. Bayer Aktiengesellschaft’s stock is up 28.3% in 2026, up 5.8% in the previous five trading days and up 70.37% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $52.2 billion with a -4.8% net profit margin. As of July 30, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.158 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

How We Compare Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc Growth Grades

Company	Ticker	Growth
Bayer Aktiengesellschaft	BAYRY	C
Bayer Aktiengesellschaft	BAYRY	C
Haleon plc	HLN	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Bayer Aktiengesellschaft has a Growth Score of 43, which is Average. Bayer Aktiengesellschaft has a Growth Score of 43, which is Average. Haleon plc has a Growth Score of 56, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc is the better investment when it comes to sustainable growth.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc’s Momentum Grades

Company	Ticker	Momentum
Bayer Aktiengesellschaft	BAYRY	A
Bayer Aktiengesellschaft	BAYRY	A
Haleon plc	HLN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bayer Aktiengesellschaft has a Momentum Score of 89, which is Very Strong. Bayer Aktiengesellschaft has a Momentum Score of 89, which is Very Strong. Haleon plc has a Momentum Score of 50, which is Average.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bayer Aktiengesellschaft	BAYRY	F
Bayer Aktiengesellschaft	BAYRY	F
Haleon plc	HLN	na

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bayer Aktiengesellschaft has a Earnings Estimate Score of 3, which is Very Negative. Bayer Aktiengesellschaft has a Earnings Estimate Score of 3, which is Very Negative. Haleon plc does not have a meaningful Earnings Estimate Score.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc is the better investment when it comes to estimate revisions.

Other Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc Grades

In addition to Estimate Revisions, Growth and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Haleon plc Stock?

Overall, Bayer Aktiengesellschaft stock has a Growth Score of 43, Momentum Score of 89 and Estimate Revisions Score of 3.

Bayer Aktiengesellschaft stock has a Growth Score of 43, Momentum Score of 89 and Estimate Revisions Score of 3.

Haleon plc stock has a Growth Score of 56, Momentum Score of 50 and Estimate Revisions Score of .

Comparing Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Haleon plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.